Robert Mulrooney
About Robert Mulrooney
Robert Mulrooney is the General Manager UK&Ireland at BeiGene, with extensive experience in the pharmaceutical industry and a background in hospital medicine and cardiology.
Company
Robert Mulrooney is currently working at BeiGene, a global biotechnology company focused on molecularly targeted and immuno-oncology drug development. He holds the position of General Manager UK & Ireland based in the London Area, United Kingdom. BeiGene's mission involves expanding access to innovative cancer treatments and developing new oncology therapies.
Title
Robert Mulrooney serves as the General Manager for the UK & Ireland at BeiGene. In this role, he is responsible for overseeing regional operations, driving market access strategies, and leading the commercialisation efforts for BeiGene's oncology portfolio across the United Kingdom and Ireland.
Education and Expertise
Robert Mulrooney has an extensive educational background in medicine and pharmaceutical sciences. He studied at University College Cork and achieved his MB; BCh; BAO in Medicine. He earned his MRCPI from The Royal College of Physicians in Ireland, followed by an FRCP from The Royal College of Physicians London. He also holds an FFPM from the Faculty of Pharmaceutical Medicine. His expertise includes internal medicine, cardiology, and pharmaceutical sciences.
Professional Background
Robert Mulrooney has a diversified professional background. Prior to BeiGene, he worked at Portola Pharmaceuticals as General Manager UK & Ireland and at Jazz Pharmaceuticals as Regional General Manager for regions including the UK, Ireland, Canada, and Italy. He founded and managed Ardiem LifeSciences. Earlier, he held various roles at GlaxoSmithKline, including Vice-President positions. His career began at Wellcome Foundation/Glaxo Wellcome and Knoll Pharmaceuticals. He also worked in hospital medicine as a Cardiology Registrar at West Middlesex University Hospital.
Achievements
Robert Mulrooney has a proven track record of delivering innovative market access solutions. Notably, he successfully launched the first monoclonal antibody treatment for osteoporosis across Europe. He has experience working with specialised medicines in areas like rare diseases, cardiovascular conditions, and haemostasis. He has also built operational biopharm teams from scratch and remains a GMC registered physician. Robert is a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Physicians in London.